(Q36691753)

15 August 2017

1 reference

title

Bupropion for weight reduction (English)

1 reference

15 August 2017

Kishore M Gadde

1

1 reference

15 August 2017

Glen L Xiong

series ordinal

2

1 reference

15 August 2017

publication date

1 January 2007

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

15 August 2017

published in

1 reference

15 August 2017

volume

7

1 reference

15 August 2017

issue

1

1 reference

15 August 2017

page(s)

17-24

1 reference

Prevalence of overweight and obesity in the United States, 1999-2004

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.1.17

Guidelines for healthy weight

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.1.17

The disease burden associated with overweight and obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.1.17

Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.1.17

Body-Mass Index and Mortality in a Prospective Cohort of U.S. Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.1.17

The efficacy and safety of sibutramine for weight loss: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.1.17

National trends in antiobesity medication use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.1.17

A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.1.17

A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.1.17

Efficacy and safety of topiramate in the treatment of obese subjects with essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.1.17

Zonisamide for weight loss in obese adults: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.1.17

Atomoxetine for weight reduction in obese women: a preliminary randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.1.17

Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.1.17

Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.1.17

Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.1.17

Metformin as treatment for overweight and obese adults: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.1.17

Differential relationships among dopamine transporter affinities and stimulant potencies of various uptake inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.1.17

Dopamine transporter availability in medication free and in bupropion treated depression: a 99mTc-TRODAT-1 SPECT study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.1.17

Bupropion occupancy of the dopamine transporter is low during clinical treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.1.17

Bupropion inhibits nicotine-evoked [(3)H]overflow from rat striatal slices preloaded with [(3)H]dopamine and from rat hippocampal slices preloaded with [(3)H]norepinephrine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.1.17

Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.1.17

Inhibition of CYP2D6 activity by bupropion

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.1.17

Serotonin syndrome induced by a combination of bupropion and SSRIs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.1.17

Linezolid-bupropion interaction as possible etiology of severe intermittent intraoperative hypertension?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.1.17

A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.1.17

Bupropion treatment of olanzapine-associated weight gain: an open-label, prospective trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.1.17

Bupropion and generalized acute urticaria: eight cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.1.17

Acute psychosis after administration of bupropion hydrochloride (Zyban).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.1.17

Intentional bupropion overdoses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.1.17

Cannabinoid-1 Receptor Antagonist, Rimonabant, for Management of Obesity and Related Risks

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.7.1.17

21 January 2018

Identifiers

DOI

10.1586/14737175.7.1.17

1 reference

15 August 2017

1 reference